Cargando…

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin (IL)-17 inhibitors are the most recent class of monoclonal antibodies approved by the FDA for psoriasis treatment. Preclinical and phase II studies of brodalumab, a high-affinity IL-17 receptor monoclonal antibody, have been encouraging. METHODS: We conducted a literature s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farahnik, Benjamin, Beroukhim, Kourosh, Abrouk, Michael, Nakamura, Mio, Zhu, Tian Hao, Singh, Rasnik, Lee, Kristina, Bhutani, Tina, Koo, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906115/ https://www.ncbi.nlm.nih.gov/pubmed/27221323 http://dx.doi.org/10.1007/s13555-016-0121-x

Ejemplares similares

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule()
por: Abrouk, Michael, et al.
Publicado: (2016)

Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule()()
por: Abrouk, Michael, et al.
Publicado: (2017)

The Patient’s Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy
por: Zhu, Tian Hao, et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 3: Biologic Injectables
por: Abrouk, Michael, et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 1: UVB Phototherapy
por: Singh, Rasnik K., et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Erythrodermic psoriasis: pathophysiology and current treatment perspectives
por: Singh, Rasnik K, et al.
Publicado: (2016)

Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability
por: Abrouk, Michael, et al.
Publicado: (2016)

Recent advances in phototherapy for psoriasis
por: Nakamura, Mio, et al.
Publicado: (2016)

Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey
por: Afifi, Ladan, et al.
Publicado: (2017)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
por: Kazemi, Tiana, et al.
Publicado: (2017)

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022)

Influence of diet on the gut microbiome and implications for human health
por: Singh, Rasnik K., et al.
Publicado: (2017)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Protocol for the safety of brodalumab regarding psychiatric comorbidities in patients with psoriasis
por: Pikou, O., et al.
Publicado: (2022)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)
por: Papp, K., et al.
Publicado: (2020)

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
por: Seo, Seong Jun, et al.
Publicado: (2020)

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
por: Coimbra, Susana, et al.
Publicado: (2014)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2023)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
por: Elgaard, Cathrine Dawn Büttner, et al.
Publicado: (2023)

The psychosocial impact of acne, vitiligo, and psoriasis: a review
por: Nguyen, Catherine M, et al.
Publicado: (2016)

Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
por: Kokolakis, Georgios, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mcup9kigf0a08tlb4gcfjjh153